Abstract
Human papillomavirus (HPV) 16 is the most oncogenic biological agents for humans. However, essential quantitative aspects of its infection cycle remain inadequately characterized. Specifically, the proportion of infected cells and the viral copy number per infected cell in cervical smears are not well understood. To address this, we employed a combination of limiting dilution techniques and Bayesian statistics on routine cervical smears to estimate the frequency of infected cells and the viral copy number per cell. Our methodology was initially validated through numerical simulations and cell culture experiments. Subsequently, we analyzed 38 HPV16-positive cervical smears, comprising 26 samples from patients without cytological lesions and 12 from patients with low-grade lesions. Our findings indicated that the substantial variability in viral load across samples predominantly stemmed from differences in the frequency of infected cells. Additionally, the mean number of HPV copies per infected cell was consistently low across all samples, ranging from approximately 2.3 to 100 copies. However, in samples with low-grade lesionMarie-Paule Algross, this number was observed to double on average. These results challenge existing assumptions regarding the biology of HPV genital infections, which are typically asymptomatic or minimally symptomatic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors acknowledge further support from the Centre National de la Recherche Scientifique, the Institut de Recherche pour le Developpement, the Agence Nationale de la Recherche contre le Sida (ANRS-MIE, to NT) and to the Labex MemoLife (to BE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
HPV16-positive samples were stored in a biobank for which a declaration on the preparation and storage of human samples for research purposes has been validated by the Ministere de l'Enseignement Superieur et de la Recherche (Paris, France), with number DC-2014-2086. HPV-negative samples came from the study "Health in climacteric women belonging to NGOs. PAPILONG study", validated by the Ethical committee of the CEI DGSP-CSISP (Valencia, Spain), with number 20210604/10/01.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://gitlab.in2p3.fr/ete/hpv16_copy_number
